BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35042069)

  • 1. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
    Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Eur J Cancer; 2022 Mar; 163():66-76. PubMed ID: 35042069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
    Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
    Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
    [No Abstract]   [Full Text] [Related]  

  • 3. mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy.
    van der Stok EP; Smid M; Sieuwerts AM; Vermeulen PB; Sleijfer S; Ayez N; Grünhagen DJ; Martens JW; Verhoef C
    Mol Oncol; 2016 Dec; 10(10):1542-1550. PubMed ID: 27692894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.
    Wada Y; Shimada M; Yamamura K; Toshima T; Banwait JK; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
    Hepatology; 2021 Sep; 74(3):1371-1383. PubMed ID: 33725402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic Profiling Reveals an Enhancer RNA Signature for Recurrence Prediction in Colorectal Cancer.
    Sahu D; Lin CC; Goel A
    Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
    Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
    Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
    Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
    Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.
    Matsuyama T; Kandimalla R; Ishikawa T; Takahashi N; Yamada Y; Yasuno M; Kinugasa Y; Hansen TF; Fakih M; Uetake H; Győrffy B; Goel A
    Int J Cancer; 2020 Dec; 147(11):3250-3261. PubMed ID: 32657428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis].
    Bao Q; Wang K; Wang HW; Jin KM; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):976-983. PubMed ID: 33053993
    [No Abstract]   [Full Text] [Related]  

  • 11. Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer.
    Lee IS; Lee H; Hur H; Kanda M; Yook JH; Kim BS; Woo Y; Kodera Y; Kim K; Goel A
    Clin Cancer Res; 2021 Apr; 27(8):2292-2300. PubMed ID: 33558424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study.
    Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC
    Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma.
    Nishiwada S; Cui Y; Sho M; Jun E; Akahori T; Nakamura K; Sonohara F; Yamada S; Fujii T; Han IW; Tsai S; Kodera Y; Park JO; Von Hoff D; Kim SC; Li W; Goel A
    Ann Surg; 2022 Dec; 276(6):e876-e885. PubMed ID: 34132691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: A transcriptomic signature that predicts cancer recurrence following hepatectomy in patients with colorectal liver metastases.
    Wang M; Li Y
    Eur J Cancer; 2022 Sep; 172():405-406. PubMed ID: 35843851
    [No Abstract]   [Full Text] [Related]  

  • 16. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of sarcopenia in patients with colorectal liver metastases undergoing hepatic resection.
    Liu YW; Lu CC; Chang CD; Lee KC; Chen HH; Yeh WS; Hu WH; Tsai KL; Yeh CH; Wee SY; Yin SM; Wang CC; Hung CH
    Sci Rep; 2020 Apr; 10(1):6459. PubMed ID: 32296122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.